triamterene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2728	396-01-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: triamterene diurene pterofen pterophene triamteren triamteril triteren	A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. Molecular weight: 253.27 Formula: C12H11N7 CLOGP: 1.61 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 129.62 ALOGS: -2.42 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

triamterene
diurene
pterofen
pterophene
triamteren
triamteril
triteren

A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.

Molecular weight: 253.27
Formula: C12H11N7
CLOGP: 1.61
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 129.62
ALOGS: -2.42
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.03 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	63 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.42 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 10, 1964	FDA	CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coronary artery disease	74.72	11.05	103	31631	33649	46620679
Myocardial infarction	52.82	11.05	166	31568	97362	46556966
Exposure during pregnancy	52.59	11.05	6	31728	108206	46546122
Off label use	52.15	11.05	113	31621	379728	46274600
Crystal nephropathy	48.50	11.05	19	31715	806	46653522
Oedema peripheral	44.15	11.05	220	31514	159486	46494842
Cerebrovascular accident	41.61	11.05	157	31577	100882	46553446
Blood potassium decreased	39.67	11.05	83	31651	37980	46616348
Rheumatoid arthritis	35.86	11.05	68	31666	240147	46414181
Osteoarthritis	33.95	11.05	106	31628	61919	46592409
Acquired haemophilia	33.12	11.05	15	31719	916	46653412
Drug ineffective	32.01	11.05	301	31433	677537	45976791
Gastrooesophageal reflux disease	31.83	11.05	117	31617	74227	46580101
Hyperlipidaemia	31.53	11.05	50	31684	18489	46635839
Synovitis	30.66	11.05	3	31731	61072	46593256
Transient ischaemic attack	30.59	11.05	71	31663	34832	46619496
Hyponatraemic encephalopathy	30.57	11.05	10	31724	249	46654079
Mitral valve incompetence	29.56	11.05	49	31685	18803	46635525
Cardiac failure congestive	29.41	11.05	132	31602	91618	46562710
Intentional overdose	28.28	11.05	5	31729	64939	46589389
Ventricular hypertrophy	27.64	11.05	22	31712	3792	46650536
Lower respiratory tract infection	26.89	11.05	3	31731	55086	46599242
Product complaint	26.88	11.05	37	31697	12064	46642264
Drug intolerance	26.25	11.05	37	31697	147012	46507316
Depression	25.33	11.05	200	31534	169904	46484424
Angina unstable	24.65	11.05	28	31706	7520	46646808
C-reactive protein increased	24.47	11.05	5	31729	58585	46595743
Hypokalaemia	24.11	11.05	121	31613	87903	46566425
Tricuspid valve incompetence	23.33	11.05	37	31697	13680	46640648
Lacunar infarction	22.93	11.05	19	31715	3466	46650862
Dizziness	22.04	11.05	339	31395	340075	46314253
Pyrexia	21.93	11.05	143	31591	348659	46305669
Injury	21.17	11.05	72	31662	43955	46610373
Blood pressure increased	21.14	11.05	153	31581	126513	46527815
Hypertension	21.08	11.05	215	31519	196141	46458187
Blood pressure inadequately controlled	20.98	11.05	20	31714	4386	46649942
Neutropenia	20.94	11.05	41	31693	143163	46511165
Ventricular tachycardia	20.06	11.05	39	31695	16928	46637400
Deep vein thrombosis	20.00	11.05	107	31627	79666	46574662
Febrile neutropenia	19.84	11.05	21	31713	94606	46559722
Abortion spontaneous	19.80	11.05	3	31731	43643	46610685
Angina pectoris	19.77	11.05	51	31683	26724	46627604
Anxiety	19.41	11.05	199	31535	181758	46472570
Focal segmental glomerulosclerosis	19.20	11.05	12	31722	1409	46652919
Product use issue	18.75	11.05	22	31712	94622	46559706
Hyponatraemia	18.42	11.05	125	31609	101207	46553121
Spinal stenosis	17.55	11.05	31	31703	12512	46641816
Blood cholesterol increased	17.14	11.05	63	31671	39950	46614378
Carpal tunnel syndrome	17.01	11.05	35	31699	15824	46638504
Overdose	16.89	11.05	27	31707	101952	46552376
Product use in unapproved indication	16.82	11.05	22	31712	90251	46564077
Chest pain	16.56	11.05	188	31546	176136	46478192
Emotional distress	16.35	11.05	52	31682	30655	46623673
General physical health deterioration	16.19	11.05	34	31700	115735	46538593
Myocardial ischaemia	15.93	11.05	30	31704	12719	46641609
Feeling abnormal	15.92	11.05	142	31592	124918	46529410
Intentional product use issue	15.88	11.05	8	31726	52772	46601556
Toxicity to various agents	15.86	11.05	82	31652	211684	46442644
Transient acantholytic dermatosis	15.61	11.05	4	31730	40	46654288
Suicide attempt	15.60	11.05	9	31725	55027	46599301
Blood triglycerides increased	15.06	11.05	28	31706	11755	46642573
Hand deformity	14.33	11.05	3	31731	34571	46619757
Hepatic function abnormal	14.24	11.05	3	31731	34418	46619910
Borderline glaucoma	14.06	11.05	3	31731	12	46654316
Diabetic neuropathy	14.01	11.05	15	31719	3774	46650554
Infusion related reaction	13.92	11.05	30	31704	101178	46553150
Diverticulum	13.54	11.05	26	31708	11180	46643148
Asthenia	13.48	11.05	291	31443	310784	46343544
Atrial fibrillation	13.37	11.05	118	31616	103472	46550856
Death	13.29	11.05	155	31579	335393	46318935
Thrombocytopenia	13.24	11.05	43	31691	126538	46527790
Pulmonary embolism	13.16	11.05	122	31612	108463	46545865
Systemic lupus erythematosus	13.07	11.05	15	31719	65165	46589163
Aortic valve incompetence	12.88	11.05	18	31716	5952	46648376
Hypertensive heart disease	12.84	11.05	12	31722	2566	46651762
Vitamin B6 deficiency	12.53	11.05	4	31730	92	46654236
Lung neoplasm	11.93	11.05	17	31717	5723	46648605
Carotid artery stenosis	11.89	11.05	16	31718	5104	46649224
Hiatus hernia	11.64	11.05	33	31701	18269	46636059
Muscle spasms	11.43	11.05	131	31603	122982	46531346
Back pain	11.28	11.05	203	31531	209836	46444492
Skin discolouration	11.21	11.05	48	31686	32632	46621696
Haemorrhoids	11.12	11.05	33	31701	18744	46635584
Fear	11.12	11.05	30	31704	16142	46638186
Arteriosclerosis	11.05	11.05	22	31712	9711	46644617

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coronary artery disease	52.66	14.01	73	9792	49639	29892974
Myocardial infarction	44.21	14.01	115	9750	125510	29817103
Cerebrovascular accident	42.06	14.01	88	9777	83389	29859224
Dizziness	27.59	14.01	132	9733	194777	29747836
Cardiac failure congestive	21.61	14.01	69	9796	84338	29858275
Bundle branch block left	19.26	14.01	15	9850	5189	29937424
Off label use	19.15	14.01	33	9832	249257	29693356
Emotional distress	17.95	14.01	24	9841	15741	29926872
Lymphopenia	16.48	14.01	21	9844	13142	29929471
Mitral valve incompetence	16.39	14.01	21	9844	13213	29929400
Arteriosclerosis coronary artery	15.88	14.01	19	9846	11157	29931456
Activated partial thromboplastin time prolonged	15.80	14.01	16	9849	7812	29934801
Chest pain	14.71	14.01	77	9788	117550	29825063
Electrocardiogram U wave present	14.59	14.01	3	9862	23	29942590

Pharmacologic Action:

Source	Code	Description
ATC	C03DB02	CARDIOVASCULAR SYSTEM DIURETICS POTASSIUM-SPARING AGENTS Other potassium-sparing agents
FDA PE	N0000008859	Decreased Renal K+ Excretion
FDA PE	N0000175359	Increased Diuresis
FDA EPC	N0000175418	Potassium-sparing Diuretic
MeSH PA	D004232	Diuretics
MeSH PA	D062686	Epithelial Sodium Channel Blockers
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D026941	Sodium Channel Blockers
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:38633	sodium channel blockers

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Edema	indication	267038008
Peripheral Edema due to Chronic Heart Failure	indication
Pulmonary Edema due to Chronic Heart Failure	indication
Hypokalemia	off-label use	43339004
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Acidosis	contraindication	51387008
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Azotemia	contraindication	445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.22	Basic
pKa2	5.5	Basic
pKa3	2.21	Basic
pKa4	0.54	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Amiloride-sensitive sodium channel, ENaC	Ion channel	P37088 P51168 P51170	SCNNA_HUMAN SCNNB_HUMAN SCNNG_HUMAN	BLOCKER	IC50	5.30	IUPHAR	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5	DRUG MATRIX
Caspase-1	Enzyme	P29466	CASP1_HUMAN		IC50	5.44	DRUG MATRIX
Cathepsin G	Enzyme	P08311	CATG_HUMAN		IC50	5.13	DRUG MATRIX
Solute carrier family 12 member 1	Transporter	Q13621	S12A1_HUMAN				WOMBAT-PK
Pteridine reductase 1	Enzyme		PTR1_LEIMA		Ki	5.47	CHEMBL

External reference:

ID	Source
4017902	VUID
N0000146253	NUI
D00386	KEGG_DRUG
4017902	VANDF
C0040869	UMLSCUI
CHEBI:9671	CHEBI
DX2	PDB_CHEM_ID
CHEMBL585	ChEMBL_ID
D014223	MESH_DESCRIPTOR_UI
5546	PUBCHEM_CID
1266	INN_ID
DB00384	DRUGBANK_ID
WS821Z52LQ	UNII
4329	IUPHAR_LIGAND_ID
10763	RXNORM
5617	MMSL
80875	MMSL
d00396	MMSL
002315	NDDF
12512008	SNOMEDCT_US
387053007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
DYAZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	0007-3650	CAPSULE	37.50 mg	ORAL	NDA	24 sections
MAXZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0460	TABLET	75 mg	ORAL	NDA	20 sections
MAXZIDE-25	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0464	TABLET	37.50 mg	ORAL	NDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-1352	TABLET	37.50 mg	ORAL	NDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-1355	TABLET	75 mg	ORAL	NDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-2537	CAPSULE	37.50 mg	ORAL	ANDA	21 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0527-1632	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0591-0348	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0591-0424	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0615-1333	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0615-3583	TABLET	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0781-2074	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0781-2715	CAPSULE	50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10135-581	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-049	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-076	TABLET	37.50 mg	ORAL	NDA	22 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-080	TABLET	75 mg	ORAL	ANDA	23 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-536	TABLET	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-537	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	16590-338	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-496	TABLET	37.50 mg	ORAL	ANDA	21 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-497	TABLET	75 mg	ORAL	ANDA	21 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-839	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	33261-365	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	33261-952	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	35356-974	CAPSULE	37.50 mg	ORAL	ANDA	24 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	42291-841	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	42291-842	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	43063-424	TABLET	37.50 mg	ORAL	NDA	22 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	45865-402	CAPSULE	37.50 mg	ORAL	ANDA	24 sections